Laekna-B has approved the issuance of 15.32 million restricted share units (RSUs) under its 2024 Share Award Scheme, according to a board announcement dated 8 May 2026.

Key grant parameters • Beneficiaries: Group employees and three executive directors—Chairman and CEO Dr. Lu Chris Xiangyang, Ms. Xie Ling and Dr. Gu Xiang-Ju Justin. • Allocation: 7.67 million RSUs to employees; 2.55 million RSUs to each of the three executive directors (total 7.65 million). • Purchase price: Nil. • Reference price: HK$13.50 per share, the closing price on the grant date.

Vesting and conditions • Schedule: 25% of each award will vest on every anniversary of the grant date over four years. • Performance hurdles: None stipulated; awards were determined after assessing past performance and expected future contributions. • Clawback: Subject to forfeiture in cases such as fraud, serious misconduct or summary dismissal, in line with the 2024 scheme rules.

Governance and shareholder approval • Independent non-executive directors have cleared the grants. • Because each director’s award equals roughly 0.57% of issued share capital—exceeding the 0.1% threshold under Listing Rule 17.04—final issuance to Dr. Lu, Ms. Xie and Dr. Gu hinges on approval by independent shareholders at the forthcoming AGM. The three directors, their associates and other core connected persons will abstain from voting.

Scheme headroom • The 2024 Share Award Scheme permits up to 39.01 million new shares. After this grant, 1.31 million shares remain available for future awards; the service-provider sub-limit is unchanged.

Strategic intent The board views the equity incentive as a tool to attract, retain and motivate talent, aligning employee and management interests with long-term shareholder value.

Investors are advised to monitor AGM documentation and exercise caution when dealing in Laekna-B securities until shareholder approval is secured.